What is the value of the 21 gene recurrence score in HER2-negative patients?
Rosman
Martin
M
Mylander
W Charles
WC
Tafra
Lorraine
L
D000077384:Anastrozole; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000235:genetics*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D009570:Nitriles / Q000008:administration & dosage; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012334:RNA, Neoplasm / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013629:Tamoxifen / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage
D000077384:Anastrozole; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009570:Nitriles; D012334:RNA, Neoplasm; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D014230:Triazoles; C508053:ERBB2 protein, human